Changing paradigms in breast cancer management: Introducing molecular genetics into the treatment algorithm

American Surgeon

Volumn 74, Issue 10, 2008, Pages 887-890

  Rayhanabad, Jessica A ^a   Difronzo, L Andrew ^a   Haigh, Phillip I ^a   Romero, Lina ^a  

^a KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR;

ADULT; AGED; ARTICLE; ASSAY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; EVALUATION; FEMALE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MOLECULAR GENETICS; PRACTICE GUIDELINE; RECURRENCE RISK; RETROSPECTIVE STUDY; ALGORITHM; BREAST TUMOR; CLINICAL TRIAL; COMPARATIVE STUDY; FOLLOW UP; GENE EXPRESSION PROFILING; GENETICS; METHODOLOGY; MIDDLE AGED; MOLECULAR BIOLOGY; MULTICENTER STUDY; PATHOLOGY; RISK FACTOR; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; ALGORITHMS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; HUMANS; MIDDLE AGED; MOLECULAR BIOLOGY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 55949114931     PISSN: 00031348     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Berry DA, Cronin KA, Pevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005;353:1784-1792 (Pubitemid 41549890)
2. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2006. CA Cancer J Clin 2006;56:106-130
3. National Cancer Institute DCCPS SRP. Cancer Statistics Branch: Surveillance, Epidemiology, and End Results (SEER) Program, SEER*Stat Database: Incidence-SEER 9 Regs Public- Use, Nov 2004 Sub (1973-2002), 2006. www.seer.cancer.gov. Accessed December 2007.
4. Fisher B, Jeong JH, Bryant J, et al. Treatment of lymphnode- negative, oestrogen-receptor-positive breast cancer: Long-term findings from National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. Lancet 2004;364:858-868
5. Fisher B, Digman J, Wolmark N, et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 1997;89:1673-1682 (Pubitemid 27508191)
6. Henderson IC, Patek AJ. The relationship between prognostic and predictive factors in the management of breast cancer. Breast Cncer Res Treat 1998;52:261-288 (Pubitemid 29056100)
7. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of Tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-2826 (Pubitemid 40051905)
8. Habel LA, Shak S, Jacobs MK, et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Research. 2006;8:R25. Available at: http://breast- cancer-research.com/ content/8/3R25. Accessed December 2007. (Pubitemid 43827376)
9. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptorpositive breast cancer. J Clin Oncol 2006;24:3726-3734 (Pubitemid 46622311)
10. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007. Update of recommendations for the use of tumor markers in breast cancer. J Clin Onc. 2007;25:5287-5312
11. National Comprehensive Cancer Network. Clinical practice guidelines in oncology. 2008. Available at: http://www.nccn.org/ professionals/physician-gls/ default.asp. Accessed December 2007.
12. Sparano G, et al. Randomized study of adjuvant combination chemotherapy and hormonal therapy versus adjuvant hormonal therapy alone in women with previously resected axillary node-negative breast cancer with various levels of risk for recurrence. (TAILORx Trial), ECOG phase III clinical trial in process.
13. Hornburger J, Cosler LK, Lyman GH. Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymphnode- negative, estrogen-receptor-positive, early stage breast cancer. Am J Manag Care 2005;11:313-324 (Pubitemid 40646936)